Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China

Table 3 Mean IOP change from baseline and mean percentage change for groups A to E at each visit

IOP parameter^a		A N = 89	B N = 33	C N = 67	D N = 18	E N = 33
Baseline	Mean IOP, mmHg	24.6 ± 4.4	18.6 ± 3.4	19.8 ± 4.0	21.4 ± 5.3	23.6 ± 5.7
1 week	IOP change, mmHg	-7.4 ± 3.8***	-2.4 ± 2.5***	-4.5 ± 3.6***	-4.0 ± 4.8**	-5.2 ± 4.8***
1 week	Percentage change	-29.7 ± 13.7	-12.3 ± 11.9	-21.7 ± 16.0	-15.6 ± 18.6	-20.8 ± 18.0
1 month	IOP change, mmHg	-8.0 ± 3.3***	-2.1 ± 2.9***	-4.6 ± 3.6***	-4.2 ± 5.2*	-6.7 ± 6.1***
1 month	Percentage change	-32.0 ± 10.2	-10.7 ± 15.5	-21.4 ± 15.5	-16.2 ± 20.8	-25.5 ± 22.7
3 months	IOP change, mmHg	-8.0 ± 3.7***	-1.9 ± 2.8***	-4.1 ± 3.5***	-5.3 ± 5.1***	-6.4 ± 6.1***
3 months	Percentage change	-32.0 ± 11.8	-9.5 ± 13.2	-18.9 ± 16.1	-21.7 ± 19.5	-24.8 ± 20.2
P value^b		0.6975	0.4192	0.1574	0.0279	0.6219

*P < 0.05, **P < 0.01, ***P < 0.001 compared with baseline IOP in this group using paired-sample t-test or Wilcoxon’s signed rank test.
^aData are presented as mean ± SD.
^bData comparison between the month-1 visit and month-3 visit in each group using paired-sample t-test or Wilcoxon’s signed rank test.
IOP intraocular pressure.
Group A: treatment-naive patients received in-trial bimatoprost monotherapy; Group B: pretrial PG mono-treated patients received in-trial switch monotherapy with bimatoprost; Group C: pretrial non-PG mono- or combination-treated patients received in-trial switch monotherapy with bimatoprost; Group D: pretrial PG combination-treated patients received in-trial PM replacement with bimatoprost; Group E: pretrial non-PG mono- or combination-treated patients received bimatoprost as an adjunctive agent in addition to the previous treatment modality.

ISSN: 1471-2415